

06 Mar 2018 | News

## QUOTED. March 6, 2018. Mary Jensen.

by

Check out what US FDA Neurological Devices Panel Chair Mary Jensen had to say about the biggest point of debate at a recent panel meeting that focused on clinical trial requirements for intracranial aneurysm devices.

"I think the biggest bone of contention here was, what do you do with small unruptured aneurysms? Do you include them in the trial?" – Mary Jensen, panel chair, FDA's Neurological Devices Panel

- Find out more: [Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions](#)

[Click here](#) for a free trial of *Medtech Insight*